December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.99 -0.01 (-0.04%)
Official Closing Price Updated: 7:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
News headline image
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside ↗
Via Stocktwits
News headline image
Looking for the most active stocks in the S&P500 index on Friday? ↗
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
News headline image
3 Stocks Under $50 We Think Twice About
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Topics Economy
News headline image
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗
Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial. 
Via Benzinga
News headline image
1 Cash-Producing Stock to Consider Right Now and 2 That Underwhelm
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
News headline image
FDA Moves To Publicize Data On Pregnant Women's Covid Vaccine Side Effects ↗
Top health officials under Kennedy are pushing for more transparency on Covid vaccine risks, focusing on pregnant women and child deaths, amid disputes with GOP lawmakers and industry leaders. 
Via Benzinga
Topics Death
News headline image
The Specter of Stagflation: A Looming Threat to Global Markets
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now ↗
With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Value Stocks We Steer Clear Of
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Why Moderna (MRNA) Shares Are Falling Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 4.8% in the afternoon session after competitors Pfizer and BioNTech announced positive topline results for their updated 2025-2026 COVID-19... 
Via StockStory
News headline image
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults ↗
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported. 
Via Benzinga
News headline image
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures ↗
The company is working on a treatment for a form of epilepsy that tends to be difficult to control. 
Via Investor's Business Daily
News headline image
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer. 
Via Investor's Business Daily
News headline image
1 Unprofitable Stock with Impressive Fundamentals and 2 That Underwhelm
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
News headline image
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
From Pfizer Inc.
Via Business Wire
News headline image
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time. ↗
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result. 
Via The Motley Fool
News headline image
Is Pfizer a Millionaire Maker? ↗
Pfizer's stock is down nearly 60% from its post-pandemic peak, opening up an opportunity for the right long-term investors. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why BioNTech Stock Crushed the Market Today ↗
The company might be close to commercializing its most advanced pipeline program. 
Via The Motley Fool
News headline image
Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.? ↗
It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure. 
Via Investor's Business Daily
News headline image
Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗
Viking aims to enter the billion-dollar weight loss drug market. 
Via The Motley Fool
News headline image
Robert F. Kennedy Took Fire From Both Republicans And Democrats Over Vaccine Overhauls: GOP Senators Defend Trump's Operation Warp Speed ↗
Secretary for Health and Human Services, Robert F. Kennedy Jr., faced bipartisan backlash during a combative Senate hearing on Thursday, as both Republicans and Democrats criticized his controversial... 
Via Benzinga
Topics Government
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields ↗
 
Via Benzinga
News headline image
10 Stocks And ETFs 'On Sale' This Month ↗
 
Via Benzinga
Topics ETFs
News headline image
These S&P500 stocks are the most active in today's session ↗
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest. 
Via Chartmill
News headline image
University of the People – an accredited, tuition free University announces record-breaking enrollment for 2025
Unprecedented Student Growth including thousands of refugees 
Via PRUnderground
News headline image
2 Top Dividend Stocks to Buy With Less Than $50 ↗
These stocks are cheap in more ways than one. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.